addS

Wednesday 29 July 2015

US Meningococcal Vaccines Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-united-states-drug-forecast-and-market-analysis-to-2022-report.html

GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.

Scope

Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in the US from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in the US

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 15

3.3 Prognosis 16

4 Disease Management 17

4.1 Meningococcal Immunization Policy 18

4.2 US 20

4.2.1 Meningococcal Immunization Recommendations and Policies 20

4.2.2 Clinical Practice 22

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Thailand Medical Equipment Manufacturers - Industry Report

Plimsoll Publishing’s Medical Equipment Manufacturers (Thailand) Analysis provides a detailed overview of the Medical Equipment Manufacturers (Thailand) market and delivers a comprehensive individual analysis on the top 50 companies, including RINCHOKECHAI CO LTD, TEGO DENTAL & CHEMICAL CO LTD and THAI ORCHID ELECTRONICS CO LTD.

To Browse a Full Report with TOC: http://www.researchmoz.us/medical-equipment-manufacturers-thailand-industry-report-report.html

This report (compiled in English language) includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Medical Equipment Manufacturers (Thailand) analysis is ideal for anyone wanting to:

See the market leaders

Identify companies heading for failure

Seek out the most attractive acquisition

Analyse industry trends

Benchmark their own financial performance

Using Plimsoll’s exclusive methodology, a quick glance of this Medical Equipment Manufacturers (Thailand) report will tell you that 6 companies have a declining Plimsoll financial rating, while 10 have shown good sales growth.

Each of the largest 50 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data.

Every business is examined on the following features:

The Plimsoll Chart: A graphical assessment of a company’s financial performance

Four year assessment of the profit/loss and balance sheet

A written summary highlighting key performance issues

Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Medical Equipment Manufacturers (Thailand) market.

This section includes:

Best Trading Partners

Sales Growth Analysis

Profit Analysis

Market Size

Rankings

Established in 1987, Plimsoll provides busy managers with a set of tools to monitor the financial welfare of their company, their rivals, or those they wish to acquire. The reports are used to assess the attractiveness of potential acquisitions, gain better understanding of a market and identify sound companies with whom to trade.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=187204

TABLE OF CONTENT

Plimsoll’s Medical Equipment Manufacturers (Thailand) analysis is the most definitive and accurate study of the Medical Equipment Manufacturers (Thailand) sector in 2013.The report (compiled in English language) is split into two sections and uses both a written and graphical analysis – analysing the 50 largest Medical Equipment Manufacturers (Thailand) companies.

The Medical Equipment Manufacturers (Thailand) report contains the most-up-to-date financial data and Plimsoll applies these figures to create their unique and authoritative analysis.

Indeed, the first section thoroughly scrutinises the market and this section includes the following:

Best Trading Partners: These are companies that are winning in both sales and financial strength – for example INHOUSE DENTAL ART CO LTD has been ranked as a best trading partner in the industry.

Sales Growth Analysis: This section reviews the fastest growing and fastest shrinking company – for example SUMMIT HEALTHCARE CO LTD is among the fastest growing.

Profit Analysis – Analysis of gross profit and pre-tax profit over the last ten years and a profitability summary comparing profits in the industry against small, medium and large companies.

Market Size: Based on the largest 50 companies, this is a comparison between last year's market size and the most current figure.

Rankings: The top 50 companies ranked by: Market Share, Sales Growth, Gross Profit and Pre-tax Profit.

The next section focuses on company analysis and provides an in-depth analysis of the largest companies within the Medical Equipment Manufacturers (Thailand) industry.

Each business is analysed using Plimsoll’s unequivocal model and culminates in the production of the Plimsoll Chart. The Plimsoll Model uses a series of charts to graphically analyse an individual company and measure its ability to achieve sales growth while maintaining financial strength.

The Plimsoll Chart is a quick and dependable method of analysing a company’s financial well-being. It’s simple to understand: a rising line is good news and a falling line is bad news.

Therefore, this company analysis will tell you if a company is:

Strong or heading for failure

Utilising their investments

Becoming burdened by debt

Getting the most from their resources

The Plimsoll Medical Equipment Manufacturers (Thailand) analysis also provides you with full business name and address, name and ages of directors and registration address.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=187204

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Spain Meningococcal Vaccines Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines Spain Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-spain-drug-forecast-and-market-analysis-to-2022-report.html

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech’s Meningitec, Novartis’ Menjugate kit, and Baxter’s NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Spain and therefore is not expected to change drastically during the forecast period. In addition, GlobalData believes that an expected change in the booster administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage rate decrease associated with the older age group may occur (MSSSI, 2013).

Scope

Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Spain from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting Spain Meningococcal Vaccines market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in Spain

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170315

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/nimenrix-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Nimenrix (Meningococcal groups A, C, Y, W-135 polysaccharide tetanus toxoid conjugate vaccine) is the brand name for GSK’s tetravalent conjugate vaccine sold in the EU to protect children, adolescents, and adults against four serogroups of N. meningitidis (A, C, Y, W-135) that cause invasive meningococcal infections. Approved in the EU 2012, Nimenrix is the first tetravalent conjugate vaccine available in Europe for patients between 12 and 23 months of age.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Nimenrix including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Nimenrix for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Nimenrix performance

Obtain sales forecast for Nimenrix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 16

3.3 Prognosis 17

4 Disease Management 18

4.1 Meningococcal Immunization Policy 19

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171849

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/neisvac-c-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

NeisVac-C (Meningococcal Serogroup C-TT Conjugate Vaccine, Adsorbed) is the brand name for Baxter’s MenC conjugate vaccine sold in the EU and Australia. First approved in the UK in 2000, NeisVac-C is one of the first meningococcal conjugate vaccines to be used in active immunization against meningococcal meningitis, specifically MenC.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on NeisVac-C including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for NeisVac-C for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of NeisVac-C performance

Obtain sales forecast for NeisVac-C from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.1.1 Etiology 11

3.1.2 Pathophysiology 13

3.2 Symptoms 14

3.3 Prognosis 15

4 Disease Management 16

4.1 Meningococcal Immunization Policy 17

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171853

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

MnB rLP2086 (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/mnb-rlp2086-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

MnB rLP2086 is Pfizer’s recombinant protein vaccine that protects against MenB disease. Despite Pfizer’s position as a major player in the vaccine industry, MnB rLP2086 is currently the only meningococcal vaccine in the pharmaceutical giant’s portfolio. Originally developed by Wyeth, Pfizer acquired MnB rLP2086 with its purchase of the company in 2009. MnB rLP2086 is a bivalent vaccine composed of two variants of the N. meningitidis OMP LP2086, A05, and B01. LP086 is a lipoprotein (LP) linked to the outer membrane of the bacteria and promotes in vivo survival by binding Factor H and facilitating complement evasion.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on MnB rLP2086 including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for MnB rLP2086 for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of MnB rLP2086 performance

Obtain sales forecast for MnB rLP2086 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Introduction 7

2.1 Catalyst 7

2.2 Related Reports 8

3 Disease Overview 10

3.1 Etiology and Pathophysiology 10

3.1.1 Etiology 10

3.1.2 Pathophysiology 12

3.2 Symptoms 13

3.3 Prognosis 14

4 Disease Management 15

4.1 Meningococcal Immunization Policy 16

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171856

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/menveo-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Menveo (Meningococcal groups A, C, Y, W-135 oligosaccharide diphtheria CRM197 conjugate vaccine) is Novartis’ tetravalent conjugate vaccine licensed in the US, EU, Australia, and Brazil to protect against four serogroups of N. meningitidis (A, C, Y, W-135) that cause meningococcal disease in children, adolescents, and adults. Approved in 2010 for all markets in this report, Menveo was the second tetravalent conjugate vaccine to enter the market in US and Australia and the first to enter the 5EU markets.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menveo including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menveo for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menveo performance

Obtain sales forecast for Menveo from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 16

3.3 Prognosis 17

4 Disease Management 18

4.1 Meningococcal Immunization Policy 19

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171848

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Menomune (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/menomune-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Menomune (Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined) is the brand name for Sanofi’s tetravalent polysaccharide vaccine sold in the US and Australia to protect against four N. meningitidis serogroups that cause meningococcal disease. Approved in the US in 1981 and Australia in 1994, Menomune was among the first available vaccines against meningococcal disease and was the standard of care in the US until the introduction of Menactra in 2005.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menomune including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menomune for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menomune performance

Obtain sales forecast for Menomune from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

2.3 Upcoming Related Reports 10

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.1.1 Etiology 11

3.1.2 Pathophysiology 13

3.2 Symptoms 14

3.3 Prognosis 15

4 Disease Management 16

4.1 Meningococcal Immunization Policy 17

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171854

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Menjugate (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Menjugate (Meningococcal Group C -CRM197 Conjugate Vaccine) is the brand name for Novartis’ MenC conjugate vaccine registered in the EU, Australia, and Brazil. The vaccine was originally developed and marketed by Wyeth (now Pfizer), and Nuron Biotech acquired Meningitec in December 2012.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menjugate including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menjugate for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menjugate performance

Obtain sales forecast for Menjugate from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.1.1 Etiology 11

3.1.2 Pathophysiology 13

3.2 Symptoms 14

3.3 Prognosis 15

4 Disease Management 16

4.1 Meningococcal Immunization Policy 17

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171852

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Menitorix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/menitorix-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Menitorix (Meningococcal Groups C and Haemophilus b Tetanus Toxoid Conjugate Vaccine) is the brand name for GSK’s Hib-MenC conjugate vaccine sold in the UK and Spain. Approved in 2012, Menitorix was the first meningococcal conjugate vaccine to also provide protection against Hib.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menitorix including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menitorix for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menitorix performance

Obtain sales forecast for Menitorix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 16

3.3 Prognosis 17

4 Disease Management 18

4.1 Meningococcal Immunization Policy 19

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171850

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines UK Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-uk-drug-forecast-and-market-analysis-to-2022-report.html

GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will shift due to changes being made to the UK MenC schedule (DOH, 2013b). Meningitec will lose sales due to its elimination from the single primary dose, with patient share expected to be made up by Menjugate and NeisVac-C.

Scope

Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in the UK from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting the UK Meningococcal Vaccines market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in the UK

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

3 Disease Overview 12

3.1 Etiology and Pathophysiology 13

3.1.1 Etiology 13

3.1.2 Pathophysiology 15

3.2 Symptoms 17

3.3 Prognosis 18

4 Disease Management 19

4.1 Meningococcal Immunization Policy 20

4.2 United Kingdom 22

4.2.1 Meningococcal Immunization Recommendations and Policies 22

4.2.2 Clinical Practice 24

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=177526

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-global-drug-forecast-and-market-analysis-to-2022-event-driven-update-report.html

GlobalData expects growth in the meningococcal vaccines market to be driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape, and an increase in the coverage rates of existing routine vaccination programs. Cost-effectiveness concerns, especially for serogroup B vaccines, will serve as a key barrier to market growth. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Highlights

Key Questions Answered

How large an impact will serotype B vaccines have on the meningococcal market? What do key opinion leaders think of these vaccines?

What are the key vaccines for each age segment and country?

Which meningococcal vaccines will face adoption challenges in the market? What is the projected uptake of new vaccines, such as Novartis Bexsero, over the forecast period?

The developmental pipeline consists of vaccines that address serotype B protection and immunogenicity in infants. Which of these vaccines will attain high sales revenues during 2012-2022 and in which markets?

What governmental and industry developments are likely to affect the vaccination rates in the markets researched? Which is the largest growth market globally?

Key Findings

Country-specific epidemiology and serotype distributions heavily influence immunization recommendations and vaccine usage.

The potential impact of serogroup B vaccines on the marketplace will be determined by their inclusion in routine vaccination programs.

Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.

Government endorsements of new and existing vaccines, in particular serogroup B vaccines, are anticipated to dramatically influence market growth.

Scope

Overview of meningococcal disease, including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.

Annualized meningococcal vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the meningococcal vaccine market.

Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically serotype B vaccines and early stage infant and pentavalent vaccines.

Analysis of the current and future market competition in the global meningococcal vaccine market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=188548

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the meningococcal vaccine market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global meningococcal vaccine market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global meningococcal vaccine market from 2012-2022.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=188548

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Meningococcal Vaccines - Current and Future Players

GlobalData has released its pharma report, “PharmaPoint: Meningococcal Vaccines Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Meningococcal Vaccines Market. The report identifies and analyses the key companies shaping and driving the global Meningococcal Vaccines market. The report provides insight into the competitive Meningococcal Vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-current-and-future-players-report.html

Scope

Investigation of current and future market competition for Meningococcal Vaccines

Competitor assessment

Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

Strategic assessment of the Meningococcal Vaccines sector through market impact analysis, future market scenario and company analysis

Reasons to buy

Gain a high level view of the trends shaping and driving the Meningococcal Vaccines Market

Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

Create an effective counter-strategy to gain a competitive advantage against those currently in the market

What’s the next big thing in the global Meningococcal Vaccines market landscape? Identify, understand and capitalize

1 Table of Contents 7

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 10

2.1 Catalyst 10

2.2 Related Reports 11

2.3 Upcoming Related Reports 11

3 Market Outlook 12

3.1 Global Markets 12

3.1.1 Forecast 12

3.1.2 Drivers and Barriers – Global Issues 16

4 Current and Future Players 20

4.1 Overview 20

4.2 Trends in Corporate Strategy 24

4.3 Company Profiles 26

4.3.1 Sanofi 26

4.3.2 Novartis 30

4.3.3 GlaxoSmithKline 34

4.3.4 Baxter 37

4.3.5 Nuron Biotech 39

4.3.6 Pfizer 41

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170319

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Meningococcal Disease - Epidemiology Forecast to 2022

Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani et al., 2006). Strains of Neisseria meningitidis are classified based on the chemical composition of unique polysaccharide capsules. Although there are 13 different serogroups, nearly all disease in humans is caused by strains representative of six serogroups: A, B, C, W-135, X and Y (CDC, 2012d; Halperin et al., 2012; Rosenstein et al., 2001). Humans are the only natural reservoir of Neisseria meningitidis, and the bacterium causes three common clinical forms of meningococcal disease: meningitis, blood infection, and pneumonia (CDC, 2012d; Wilder-Smith and Memish, 2003). Up to 10% of adolescents and adults are asymptomatic, transient carriers of the bacterium, which can be transmitted via respiratory droplets or by direct contact (CDC, 2012d).

To Browse a Full Report with TOC: http://www.researchmoz.us/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html

During the forecast period, the number of incident cases will remain relatively stable. An increase in international travel to regions of high incidence could cause some serogroups to appear in countries where they were not previously prevalent. In addition to vaccinating international travelers, the vaccination of household members of individuals traveling to high-risk regions would further prevent outbreaks due to strains that certain populations are not yet immune to.

GlobalData epidemiologists obtained surveillance data for each market in this analysis, except for Spain and the UK. However, for these markets a peer-reviewed journal article was used that analyzed the surveillance data in these countries. The surveillance data used in this analysis are collected by country-specific, governmental organizations that routinely collect data on meningococcal disease cases. Use of surveillance data is optimal as it allows for a comprehensive picture of the epidemiology of the disease, including age and serogroup distribution. Although the overall incidence of meningococcal disease is relatively low, the age and serogroup segmentation of incident cases provided in this forecast shows the populations at highest risk for meningococcal disease in each market.

Scope

The Meningococcal Disease EpiCast Report provides an overview of the risk factors and global trends of meningococcal disease in the eight major markets (US, France, Germany, Italy, Spain, UK, Australia, and Brazil).

It includes a 10-year epidemiology forecast of meningococcal disease incident cases segmented by age (<1, 14, 514, 1524, 2544, 4564, and ending at ages 65 years and older) and serogroup (B, C, Y, and W-135) in the 8MM.

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global meningococcal disease market.

Quantify patient populations in the global meningococcal disease market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and serogroups that present the best opportunities for meningococcal disease vaccines in each of the markets covered.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=168117

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/meningitec-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Meningitec (Meningococcal Serogroup C Diphtheria CRM197 Conjugate Vaccine, Adsorbed) is the brand name for Nuron Biotech’s MenC conjugate vaccine sold in the EU and Australia. The vaccine was originally developed and marketed by Wyeth (now Pfizer), and Nuron Biotech acquired Meningitec in December 2012.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Meningitec including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Meningitec for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Meningitec performance

Obtain sales forecast for Meningitec from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.1.1 Etiology 11

3.1.2 Pathophysiology 13

3.2 Symptoms 14

3.3 Prognosis 15

4 Disease Management 16

4.1 Meningococcal Immunization Policy 17

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171851

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Menactra (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

To Browse a Full Report with TOC: http://www.researchmoz.us/menactra-meningococcal-vaccines-forecast-and-market-analysis-to-2022-report.html

Menactra (Meningococcal Groups A, C, Y, W-135 polysaccharide diphtheria toxoid conjugate vaccine) is the brand name for Sanofi’s tetravalent conjugate vaccine sold in the US and Australia to protect children, adolescents, and adults against four serogroups of N. meningitidis that cause invasive meningococcal disease. In 2005, Menactra became the first conjugate vaccine to be approved in the US for those 11 to 55 years of age. Approval was expanded to those from two to 55 years of age in the US in 2007, and to those as young as nine months of age in 2011, and it was also licensed for use in Australia in 2011.

Scope

Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Menactra including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Menactra for the top nine countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Menactra performance

Obtain sales forecast for Menactra from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 14

3.2 Symptoms 16

3.3 Prognosis 17

4 Disease Management 18

4.1 Meningococcal Immunization Policy 19

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=171847

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Medical Equipment Wholesalers (Nordic) - Industry Report

Plimsoll Publishing’s Medical Equipment Wholesalers (Nordic) Analysis provides a detailed overview of the Medical Equipment Wholesalers (Nordic) market and delivers a comprehensive individual analysis on the top 100 companies, including ABBOTT LABORATORIES A/S, BROCK & MICHELSEN A/S and COVIDIEN FINLAND OY.

To Browse a Full Report with TOC: http://www.researchmoz.us/medical-equipment-wholesalers-nordic-industry-report-report.html

This report (compiled in English language) includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Medical Equipment Wholesalers (Nordic) analysis is ideal for anyone wanting to:

See the market leaders

Identify companies heading for failure

Seek out the most attractive acquisition

Analyse industry trends

Benchmark their own financial performance

Using Plimsoll’s exclusive methodology, a quick glance of this Medical Equipment Wholesalers (Nordic) report will tell you that 5 companies have a declining Plimsoll financial rating, while 18 have shown good sales growth.

Each of the largest 100 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data.

Every business is examined on the following features:

The Plimsoll Chart: A graphical assessment of a company’s financial performance

Four year assessment of the profit/loss and balance sheet

A written summary highlighting key performance issues

Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Medical Equipment Wholesalers (Nordic) market.

This section includes:

Best Trading Partners

Sales Growth Analysis

Profit Analysis

Market Size

Rankings

Established in 1987, Plimsoll provides busy managers with a set of tools to monitor the financial welfare of their company, their rivals, or those they wish to acquire. The reports are used to assess the attractiveness of potential acquisitions, gain better understanding of a market and identify sound companies with whom to trade.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=186246

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Medical Equipment Wholesalers (Asia) - Industry Report

Plimsoll Publishing’s Medical Equipment Wholesalers (Asia) Analysis provides a detailed overview of the Medical Equipment Wholesalers (Asia) market and delivers a comprehensive individual analysis on the top 1000 companies, including CONG TY CO PHAN HOA - DUOC PHAM MEKOPHAR, CONG TY CO PHAN DUOC DANAPHA and YAGAMI SEISAKUSHO CO.,LTD..

To Browse a Full Report with TOC: http://www.researchmoz.us/medical-equipment-wholesalers-asia-industry-report-report.html

This report (compiled in English language) includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Medical Equipment Wholesalers (Asia) analysis is ideal for anyone wanting to:

See the market leaders

Identify companies heading for failure

Seek out the most attractive acquisition

Analyse industry trends

Benchmark their own financial performance

Using Plimsoll’s exclusive methodology, a quick glance of this Medical Equipment Wholesalers (Asia) report will tell you that 81 companies have a declining Plimsoll financial rating, while 303 have shown good sales growth.

Each of the largest 1000 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data.

Every business is examined on the following features:

The Plimsoll Chart: A graphical assessment of a company’s financial performance

Four year assessment of the profit/loss and balance sheet

A written summary highlighting key performance issues

Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Medical Equipment Wholesalers (Asia) market.

This section includes:

Best Trading Partners

Sales Growth Analysis

Profit Analysis

Market Size

Rankings

Established in 1987, Plimsoll provides busy managers with a set of tools to monitor the financial welfare of their company, their rivals, or those they wish to acquire. The reports are used to assess the attractiveness of potential acquisitions, gain better understanding of a market and identify sound companies with whom to trade.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=186734

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Medical Equipment Markets in China

China's demand for medical equipment has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.

To Browse a Full Report with TOC: http://www.researchmoz.us/medical-equipment-markets-in-china-report.html

Table Of Content

Table of Content

I. INTRODUCTION

Report Scope and Methodology

Executive Summary

II. BUSINESS ENVIRONMENT

Economic Outlook

Key Economic Indicators

Industrial Output

Population and Labor

Foreign Investment

Foreign Trade

Financial and Tax Regulations

Banking System and Regulations

Foreign Exchange

Taxes, Tariff and Custom Duties

III. MEDICAL EQUIPMENT INDUSTRY ASSESSMENTS

Medical Equipment Industry Structure

Market Size

Market Growth Drivers

Major Producer Facility Locations and Output

Market Share of Key Producers

Labor Costs

Potential Entrants

Major End-Users

Major Distributors

Potential Entrants

Major Foreign Investments

Technology Development

IV. MEDICAL EQUIPMENT PRODUCTION AND DEMAND

Overview

Medical Equipment Production and Demand (Yuan)

Surgical Equipment

Surgical Hand Instrument

Orthopedic Instruments

Non-Electronic Diagnostic Metrical Instrument

Dental Equipment

X-Ray Equipment

Electro-Medical Equipment

Electrocardiographs (EKG)

Electroencephalographs (EEG)

Electromyography (EMG)

Ultrasonic Scanning Devices

Nuclear Magnetic Resonance Imaging Equipment (MRI)

Audiological Equipment

Endoscopes Equipment

Electronic Therapeutic Equipment

Electronic Physical Therapy Equipment

Intensive Care/Coronary Care Monitors

Patient Monitors

Surgical Life Support Systems

Other Medical Equipment

Medical Equipment Imports and Exports

Demand of Medical Equipment by Region

Pricing Trends

V. MEDICAL EQUIPMENT CONSUMPTION BY MARKET

Medical Equipment Markets Outlook Overview

Government Regulations

Health Care Insurance Industry Overview

Consumer Spending Trends

Demographic Trends

Health Care Industry Trends

Hospitals and Hospital Beds

VI. MARKETING STRATEGIES

China Market Entry Overview

China’s Distribution System

Advanced Materials Distribution Channels

Transportation and Freight Infrastructure

Communications

China’s Market Entry

Export to China

Indirect Export

Direct Export

License and Contract Manufacture

Assembling in China

Contract Manufacturing

Trade Permit

Investment

Equity Joint Venture

Contractual Joint Venture

Wholly Foreign-Owned Enterprise

VII. MEDICAL EQUIPMENT PRODUCER DIRECTORY

Medical Equipment Producer Profiles

Distributors and Trading Companies

Research Institutions and Associations

List of Tables

I. INTRODUCTION

Economic Outlook Summary

Medical Equipment Supply and Demand Summary

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=193031

II. BUSINESS ENVIRONMENT

Key Economic Indicators

Industrial Output

Population and Labor Force Trends

Foreign Investment and Loans

Foreign Trade

Key Commodity Exports from China

China’s Exports to its Leading Trade Partners

Key Commodity Imports into China

China’s Imports from Its Leading Trade Partners

III. MEDICAL EQUIPMENT INDUSTRY ASSESSMENTS

Major Producer Facility Locations

Major Medical Equipment Producer Output

Market Share of Key Producers

Major Foreign Investments

IV. MEDICAL EQUIPMENT PRODUCTION AND DEMAND

Total Medical Equipment Production and Demand

Medical Equipment Production and Demand (Yuan)

Surgical Equipment

Surgical Hand Instrument

Orthopedic Instruments

Non-Electronic Diagnostic Metrical Instrument

Dental Equipment

X-Ray Equipment

Electro-Medical Equipment

Electrocardiographs (EKG)

Electroencephalographs (EEG)

Electromyography (EMG)

Ultrasonic Scanning Devices

Nuclear Magnetic Resonance Imaging Equipment (MRI)

Audiological Equipment

Endoscopes Equipment

Electronic Therapeutic Equipment

Electronic Physical Therapy Equipment

Intensive Care/Coronary Care Monitors

Patient Monitors

Surgical Life Support Systems

Other Medical Equipment

Demand of Medical Equipment by Region

Medical Equipment Imports and Exports

V. MEDICAL EQUIPMENT CONSUMPTION BY MARKET

Total Medical Equipment Consumption by Market

Consumer Spending Trends

Demographic Trends

Health Care Industry Trends

Hospitals and Hospital Beds

List of Figures

Medical Equipment Production and Demand Summary

China's GDP and Industrial Output

Industrial Output by Ownership

Foreign Investments and Loans

China’s Imports and Exports

Medical Equipment Output in China

Medical Equipment Production and Demand

Medical Equipment Exports and Imports

Medical Equipment Demand by Market

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=193031

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Medical Equipment and Supply Markets in China (7 Full Research Reports Collection)

China's demand for medical equipment and supply markets has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This is a collection of 7 full market research reports on disposalbe medical supplies, medical equipment, healthcare, oral care products, dental equipment, eye care products, and blood products. These new studies examine China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in China are profiled.

Table Of Content

Contact customer services for Table of Contents of all these reports

To Browse a Full Report with TOC: http://www.researchmoz.us/medical-equipment-and-supply-markets-in-china-7-full-research-reports-collection-report.html

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=113959

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Korea Medical Equipment Manufacturers - Industry Report

Plimsoll Publishing’s Medical Equipment Manufacturers (Korea) Analysis provides a detailed overview of the Medical Equipment Manufacturers (Korea) market and delivers a comprehensive individual analysis on the top 300 companies, including GE HEALTHCARE KOREA CO.,LTD., HUVITZ CO.,LTD. and COMED MEDICAL SYSTEMS CO.,LTD.

To Browse a Full Report with TOC: http://www.researchmoz.us/medical-equipment-manufacturers-korea-industry-report-report.html

This report (compiled in English language) includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Medical Equipment Manufacturers (Korea) analysis is ideal for anyone wanting to:

See the market leaders

Identify companies heading for failure

Seek out the most attractive acquisition

Analyse industry trends

Benchmark their own financial performance

Using Plimsoll’s exclusive methodology, a quick glance of this Medical Equipment Manufacturers (Korea) report will tell you that 87 companies have a declining Plimsoll financial rating, while 114 have shown good sales growth.

Each of the largest 300 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data.

Every business is examined on the following features:

The Plimsoll Chart: A graphical assessment of a company’s financial performance

Four year assessment of the profit/loss and balance sheet

A written summary highlighting key performance issues

Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Medical Equipment Manufacturers (Korea) market.

This section includes:

Best Trading Partners

Sales Growth Analysis

Profit Analysis

Market Size

Rankings

Established in 1987, Plimsoll provides busy managers with a set of tools to monitor the financial welfare of their company, their rivals, or those they wish to acquire. The reports are used to assess the attractiveness of potential acquisitions, gain better understanding of a market and identify sound companies with whom to trade.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=186147

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Italy Meningococcal Vaccines Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines Italy Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-italy-drug-forecast-and-market-analysis-to-2022-report.html

GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Total sales in this segment of the market will decline slightly due to a population decrease in the targeted age group of 12–24 months of age. GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech’s Meningitec, Novartis’ Menjugate, and Baxter’s NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Italy and therefore is not expected to change drastically during the forecast period.

Scope

Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Italy from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting Italy Meningococcal Vaccines market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2012-2022 in Italy

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170314

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074

Global MRI Medical Equipment Industry 2014 Market Research Report

<2014 Market Research Report on Global MRI Medical Equipment Industry> was a professional and depth research report on Global MRI Medical Equipment industry that you would know the world's major regional market conditions of MRI Medical Equipment industry, the main region including North American, Europe and Asia etc, and the main country including United States ,Germany ,Japan and China etc.

To Browse a Full Report with TOC: http://www.researchmoz.us/global-mri-medical-equipment-industry-2014-market-research-report-report.html

The report firstly introduced MRI Medical Equipment basic information including MRI Medical Equipment definition classification application and industry chain overview; MRI Medical Equipment industry policy and plan, MRI Medical Equipment product specification, manufacturing process, cost structure etc. Then we deeply analyzed the world's main region market conditions that including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc.

In the end, the report introduced MRI Medical Equipment new project SWOT analysis, investment feasibility analysis, and investment return analysis and Global MRI Medical Equipment industry.

In a word, it was a depth research report on Global MRI Medical Equipment industry. And thanks to the support and assistance from MRI Medical Equipment industry chain related technical experts and marketing experts during Research Team survey and interviews.

The report including six parts, the first part maainly introduced the product basic information; the second parts mainly analyzed the Asia MRI Medical Equipment industry; the third part mainly analyzed the North American MRI Medical Equipment industry; the fourth part mainly analyzed the Europe MRI Medical Equipment industry; the fifth part mainly analyzed the market entry and investment feasibility; the sixth part was the report conclusion chapter.

To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=220945

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Email: sales@researchmoz.us

Blog: http://dynamicmarketresearch.blogspot.com/

Tel: 866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-621-2074